April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Visual Recovery and OCT Changes Following Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy with Levodopa, Allopurinol and Tetracycline
Author Affiliations & Notes
  • Lenworth N Johnson
    Ophthalmology, Alpert Medical School of Brown University/Rhode Island Hospital, Providence, RI
    Ophthal-Sch of Med, University of Missouri-Columbia, Columbia, MO
  • Deanna P Harris Lyttle
    Ophthal-Sch of Med, University of Missouri-Columbia, Columbia, MO
  • Gregory F Petroski
    Biostatistics, University of Missouri-Columbia, Columbia, MO
  • Footnotes
    Commercial Relationships Lenworth Johnson, None; Deanna Harris Lyttle, None; Gregory Petroski, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6220. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lenworth N Johnson, Deanna P Harris Lyttle, Gregory F Petroski; Visual Recovery and OCT Changes Following Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy with Levodopa, Allopurinol and Tetracycline. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6220.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine the effectiveness of levodopa alone or in combination with allopurinol and tetracycline on visual acuity, visual field, and retinal nerve fiber layer (RNFL) thickness in eyes affected by nonarteritic anterior ischemic optic neuropathy (NAION).

Methods: Retrospective cohort study involving 33 eyes of 33 patients from 119 consecutively evaluated patients with NAION. Patients evaluated within 45 days of NAION onset and who had at least one optical coherence tomography (OCT) within 1 year of NAION onset were enrolled. Patients received treatment with levodopa alone (Levodopa only) or in combination with allopurinol and tetracycline (Levodopa plus). Best corrected visual acuity converted to logMAR, mean deviation (MD) threshold sensitivity on automated perimetry, and RNFL thickness on OCT were recorded at initial visit and follow-up within 1 year of NAION onset. Primary outcome measures were changes in logMAR visual acuity, MD threshold sensitivity, and RNFL thickness.

Results: Improvement in visual acuity by 3 or more lines was documented for 71% (5 of 7) of Levodopa only and 50% (4 of 8) of Levodopa plus eyes having an initial visual acuity of 20/60 or worse. No levodopa treated eye had worsened visual acuity. There was no significant difference (p=0.91) between the change in logMAR visual acuity for the Levodopa only (-0.43 logMAR) and Levodopa plus (-0.4 logMAR) groups. There was no significant difference (p=0.9) between the change in MD threshold sensitivity for Levodopa only (1.79 dB) and Levodopa combined (1.54 dB) groups. The average RNFL thickness decreased by 23.6% for levodopa treated eyes, in contrast with previously published reports which documented decrease in average RNFL thickness of 35% to 42% for untreated patients.

Conclusions: Treatment within 45 days of onset of NAION with levodopa alone or in combination with allopurinol and tetracycline improved visual acuity but not visual field. Levodopa may promote neuroprotection in NAION by decreasing retinal ganglion cell loss and subsequent RNFL thinning.

Keywords: 613 neuro-ophthalmology: optic nerve • 615 neuroprotection • 502 dopamine  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×